Monitoring cognitive impairment through speech

Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analyzing speech alone, we can detect cognitive impairment associated with dementia and mental illness. Our assessment can be used in life science research, senior care and clinical settings.

@@alt

A biomarker for clinical research

Paper-based cognitive assessments are slow, subjective and often coarse. Winterlight has developed a speech-based cognitive assessment that analyzes short snippets of speech and uses AI to objectively measure cognition via hundreds of vocal biomarkers in speech and language. Winterlight can support clinical trials and studies for a wide range of central nervous system disorders.

Work with us
@@alt

Tracking cognitive wellness in senior care

It is challenging to care for seniors with complex medical needs and frequently with cognitive impairments. Combined with your existing health data, we identify seniors at-risk of cognitive or functional decline. Our assessment can help you provide better proactive care at a time when it is most needed to have the greatest impact on the health and happiness of your residents.

Reach us here
@@alt

Winterlight’s Healthy Aging Study

We are building better tools so that we can identify risk for dementia more quickly and at an earlier age. This will allow researchers to better understand the disease and work towards a cure. If you are healthy and 50 years or older in the Greater Toronto Area, we would like your help on learning the effect of the aging process on the brain.

Tell me more

Developed in partnership with:



What's new

March 2020

Vivoryon partners with Winterlight for upcoming clinical trial

Vivoryon Therapeutics will use the Winterlight speech assessment in upcoming Phase 2b clinical trial of PQ912 in Alzheimer’s Disease.

Read Read More
February 2020

Winterlight presents new findings on speech changes in Alzheimer’s at ISCTM 2020

Winterlight presented new research from a longitudinal study of Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) today at the 16th Annual Meeting of the International Society for CNS Clinical Trials and Methodology.

Read Read More
January 2020

Pear Therapeutics licenses Winterlight technology

Winterlight Labs has entered into an agreement with Pear Therapeutics to develop speech-based biomarkers to improve the efficacy of prescription digital therapeutics.

Read Read More
December 2019

Winterlight presents updates on speech-based digital biomarker development at CTAD 2019

Today at the Clinical Trials for Alzheimer’s Disease (CTAD) Conference, Winterlight presented preliminary data on a speech-based language composite score for Frontotemporal Dementia and improved tracking of cognitive decline in Healthy Seniors.

Read Read More
November 2019

Winterlight Labs raises $5.6M in series A funding in round led by Hikma Ventures

Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.

Read Read More

Get in touch

Mailing Address

Winterlight Labs
46 Hayden St
Suite 400
Toronto
Ontario, Canada
M4Y 1V8

Send us a message